DYN logo

DYN
Dyne Therapeutics Inc

2,693
Mkt Cap
$3.08B
Volume
1.24M
52W High
$25.00
52W Low
$7.01
PE Ratio
-5.27
DYN Fundamentals
Price
$18.68
Prev Close
$19.36
Open
$19.68
50D MA
$17.25
Beta
1.86
Avg. Volume
2.67M
EPS (Annual)
-$3.47
P/B
3.17
Rev/Employee
$0.00
$1,570.98
Loading...
Loading...
News
all
press releases
Darwin Wealth Management LLC Sells 58,250 Shares of Dyne Therapeutics, Inc. $DYN
Darwin Wealth Management LLC decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 33.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN
Aberdeen Group plc raised its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 99.0% in the 4th quarter, according to the company in its most recent filing with the Securities...
MarketBeat·6d ago
News Placeholder
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN
SG Americas Securities LLC bought a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 265,384 shares of the company's stock, valued at...
MarketBeat·10d ago
News Placeholder
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has received an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold ratin...
MarketBeat·18d ago
News Placeholder
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,365,245 shares of the company's stock after purchasing an additional 278,466...
MarketBeat·21d ago
News Placeholder
Dyne Therapeutics (NASDAQ:DYN) Trading 4.4% Higher - Here's Why
Dyne Therapeutics (NASDAQ:DYN) Trading Up 4.4% - Here's What Happened...
MarketBeat·23d ago
News Placeholder
Dyne Therapeutics Targets 2026 Breakout Year With DMD BLA Plans and DM1 Milestones at Stifel Conference
Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion with Stifel, emphasizing plans to transition toward a commercial-stage...
MarketBeat·24d ago
News Placeholder
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN
Braidwell LP trimmed its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 16.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·28d ago
News Placeholder
WINTON GROUP Ltd Makes New Investment in Dyne Therapeutics, Inc. $DYN
WINTON GROUP Ltd acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·1mo ago
News Placeholder
Insider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Purchases 3,000 Shares of Stock
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Brian Posner bought 3,000 shares of the business's stock in a transaction on Friday, March 6th. The stock was purchased at an average...
MarketBeat·1mo ago
<
1
2
...
>

Latest DYN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.